MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lewy bodies"

  • 2017 International Congress

    Impaired Color Vision in Patients with DLB or Prodromal DLB.

    B. Tousi, P. Flanigan, M. Khosravi (Cleveland, OH, USA)

    Objective: We sought to characterize the prevalence of color vision impairment in DLB patients and investigate how color vision impairment in DLB patients was associated with other…
  • 2017 International Congress

    Association of arterial stiffness with cognition in patients with Lewy body disorder

    J.Y. LEE, D.-W. Ryu, J.-S. Kim (Seoul, Republic of Korea)

    Objective: We aimed to investigate the association between arterial stiffness and cognitive function in patients with Lewy body disorder (LBD), including Parkinson disease (PD) and…
  • 2017 International Congress

    Striatal dopamine transporter abnormalities in pure autonomic failure and speculation about the relationship with Lewy bodies

    M. Yogo, M. Morita, M. Suzuki (Tokyo, Japan)

    Objective: To reveal dopamine transporter (DAT) abnormalities in pure autonomic failure (PAF) and speculate about the relationship with the Lewy body progression pathway.    Background:…
  • 2017 International Congress

    Characterization of Noncoding Variant(s) Driving Genome-Wide Association of the PARK10 Locus in Autopsy-Proven Parkinson Disease and Controls.

    J. Vance, K. Nuytemans, D. Gveric, L. Gomez, G. Beecham, E. Martin, W. Scott (Miami, FL, USA)

    Objective: Confirm the PARK10 locus as a major GWAS locus in autopsy-confirmed (AC) PD and AC controls and identify potential noncoding variants driving the association. …
  • 2017 International Congress

    Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease

    K. Kashihara, M. Kitayama, T. Hamaguchi (Okayama, Japan)

    Objective: In the present study, we tried to elucidate if the occipital hypometabolism detected by [(18) F]-fluoro-d-glucose (FDG) positron emission tomography (PET) scan in patients with idiopathic…
  • 2016 International Congress

    The clinical characteristics of Lewy body disease showed autonomic failures preceding motor signs

    A. Miyake, T. Yamamoto, K. Ikeda, T. Furuya, M. Takashi, Y. Ito, Y. Nakazato, N. Tamura, N. Araki (Irumagun Moroyama Town, Japan)

    Objective: There are few cases of Lewy body disease who have been initially diagnosed as pure autonomic failure(PAF), because they had only autonomic symptoms for…
  • 2016 International Congress

    Utility of the Mayo sleep questionnaire in predicting final autopsy diagnosis of alpha-synucleinopathy

    D. Shprecher, J. Hentz, C. Adler, B. Dugger, H. Shill, E. Driver-Dunkley, S. Mehta, M. Sabbagh, C. Belden, R. Savica, L. Sue, T. Beach (Sun City, AZ, USA)

    Objective: To ascertain the utility of the MSQ in predicting final autopsy diagnosis of an alpha-synuleinopathy. Background: Idiopathic REM sleep behavior disorder (iRBD) is a…
  • 2016 International Congress

    Safety of nelotanserin in a randomized placebo-controlled phase 2 study

    W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, S. Piscitelli, M. Sanchez, W. Shanahan (New York, NY, USA)

    Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…
  • 2016 International Congress

    Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

    W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

    Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…
  • 2016 International Congress

    Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia

    W. Wen, K. Kishnani, S. Ramaswamy, S. Piscitelli (New York, NY, USA)

    Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley